OraSure Gains After FDA Clears At-Home Urine Kit for STI Molecular Testing
OraSure Technologies' stock rose in premarket trading after the company announced FDA clearance for its Colli-Pee Dx urine collection kit paired with Roche cobas molecular systems, enabling at-home first-void urine collection for multiple STIs and a mail-in testing workflow for laboratories and health systems.